- CH₣171.98bn
- CH₣186.66bn
- $51.72bn
- 97
- 32
- 91
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.87 | ||
| PEG Ratio (f) | 0.75 | ||
| EPS Growth (f) | 20.55% | ||
| Dividend Yield (f) | 3.72% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.78 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 15.26 | ||
| Price to Sales | 4.07 | ||
| EV to EBITDA | 12.06 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.46% | ||
| Return on Equity | 26.33% | ||
| Operating Margin | 27.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 49,898 | 43,974 | 43,375 | 46,660 | 51,722 | 53,583.76 | 54,662.58 | 1.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.94 | +139.77 | -66.01 | +51.77 | +20.69 | +29.57 | +4.21 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Directors
- Joerg Reinhardt NEC (66)
- Vasant Narasimhan CEO (46)
- Enrico Vanni NVC (71)
- Harry Kirsch CFO (57)
- Robert Kowalski CHO (54)
- Steffen Lang CTO (55)
- Klaus Moosmayer CCO (54)
- James Bradner EXB (50)
- Karen Hale EXB (54)
- Richard Saynor EXB (55)
- Susanne Schaffert EXB (55)
- John Tsai EXB (55)
- Marie-France Tschudin EXB (50)
- Robert Weltevreden EXB (53)
- Charlotte Pamer- Wieser SEC
- Nancy Andrews NID (64)
- Ton Buechner NID (56)
- Patrice Bula NID (66)
- Elizabeth Doherty NID (65)
- Ann Fudge NID (71)
- Bridgette Heller NID (60)
- Simon Moroney NID (63)
- Charles Sawyers NID (63)
- Frans van Houten NID (62)
- Andreas von Planta NID (66)
- William Winters NID (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 1st, 1996
- Public Since
- May 7th, 2001
- No. of Shareholders
- 186,096
- No. of Employees
- 75,883
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
SIX Swiss Exchange- Shares in Issue
- 1,897,580,618
- Address
- Lichtstrasse 35, BASEL, 4056
- Web
- https://www.novartis.com/
- Phone
- +41 613241111
- Auditors
- KPMG AG
Latest News for NOVN
Upcoming Events for NOVN
Q1 2025 Novartis AG Earnings Release
Q1 2025 Novartis AG Earnings Call
Novartis AG at Bank of America Global Healthcare Conference
Novartis AG at Redburn Atlantic Canada Conference
Novartis AG at Bernstein Strategic Decisions Conference
Novartis AG at Jefferies Global Healthcare Conference
Novartis AG at Goldman Sachs Global Healthcare Conference
Novartis AG at Commerzbank and ODDO BHF SWISS Equities Conference
Novartis AG at Citi European Healthcare Conference
Novartis AG at JPMorgan European Healthcare Forum
Q2 2025 Novartis AG Earnings Release
Similar to NOVN
Cosmo Pharmaceuticals NV
SIX Swiss Exchange
Curatis Holding AG
SIX Swiss Exchange
Dottikon Es Holding AG
SIX Swiss Exchange
Galenica AG
SIX Swiss Exchange
PolyPeptide AG
SIX Swiss Exchange
FAQ
As of Today at 22:21 UTC, shares in Novartis AG are trading at CH₣90.63. This share price information is delayed by 15 minutes.
Shares in Novartis AG last closed at CH₣90.63 and the price had moved by +6.81% over the past 365 days. In terms of relative price strength the Novartis AG share price has outperformed the FTSE Global All Cap Index by +4.93% over the past year.
The overall consensus recommendation for Novartis AG is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Novartis AG dividend yield is 3.47% based on the trailing twelve month period.
Last year, Novartis AG paid a total dividend of $3.86, and it currently has a trailing dividend yield of 3.47%. We do not have any data on when Novartis AG is to next pay dividends.
We do not have data on when Novartis AG is to next pay dividends. The historic dividend yield on Novartis AG shares is currently 3.47%.
To buy shares in Novartis AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣90.63, shares in Novartis AG had a market capitalisation of CH₣171.98bn.
Here are the trading details for Novartis AG:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: NOVN
Based on an overall assessment of its quality, value and momentum Novartis AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Novartis AG is CH₣103.21. That is 13.88% above the last closing price of CH₣90.63.
Analysts covering Novartis AG currently have a consensus Earnings Per Share (EPS) forecast of $8.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Novartis AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -7.94%.
As of the last closing price of CH₣90.63, shares in Novartis AG were trading -5.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Novartis AG PE ratio based on its reported earnings over the past 12 months is 12.87. The shares last closed at CH₣90.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Novartis AG's management team is headed by:
- Joerg Reinhardt - NEC
- Vasant Narasimhan - CEO
- Enrico Vanni - NVC
- Harry Kirsch - CFO
- Robert Kowalski - CHO
- Steffen Lang - CTO
- Klaus Moosmayer - CCO
- James Bradner - EXB
- Karen Hale - EXB
- Richard Saynor - EXB
- Susanne Schaffert - EXB
- John Tsai - EXB
- Marie-France Tschudin - EXB
- Robert Weltevreden - EXB
- Charlotte Pamer- Wieser - SEC
- Nancy Andrews - NID
- Ton Buechner - NID
- Patrice Bula - NID
- Elizabeth Doherty - NID
- Ann Fudge - NID
- Bridgette Heller - NID
- Simon Moroney - NID
- Charles Sawyers - NID
- Frans van Houten - NID
- Andreas von Planta - NID
- William Winters - NID